Cytokinetics (CYTK) had the highest return between December 1, 2023 and January 3, 2024 by a mid-cap US stock, returning 158.4%.
| ASSET | DATE | % RETURN |
|---|---|---|
Cytokinetics (CYTK) | 12/1/2023 - 1/3/2024 | 158.4% |
Mercurity Fintech Holding Inc ADR (MFH) | 12/1/2023 - 1/3/2024 | 152.66% |
Sezzle (SEZL) | 12/1/2023 - 1/3/2024 | 112.21% |
Arcutis Biotherapeutics (ARQT) | 12/1/2023 - 1/3/2024 | 111.35% |
Ocular Therapeutix (OCUL) | 12/1/2023 - 1/3/2024 | 81.6% |
Terawulf (WULF) | 12/1/2023 - 1/3/2024 | 80.67% |
CleanSpark (CLSK) | 12/1/2023 - 1/3/2024 | 78.85% |
Bitdeer Technologies Group Class A Ordinary Shares (BTDR) | 12/1/2023 - 1/3/2024 | 73.59% |
Ondas (ONDS) | 12/1/2023 - 1/3/2024 | 73.15% |
CommScope (COMM) | 12/1/2023 - 1/3/2024 | 65.48% |
GeneDx (WGS) | 12/1/2023 - 1/3/2024 | 62.21% |
Liquidia Technologies (LQDA) | 12/1/2023 - 1/3/2024 | 58.52% |
Compania de Minas Buenaventura SAA ADR (BVN) | 12/1/2023 - 1/3/2024 | 51.84% |
Compass (COMP) | 12/1/2023 - 1/3/2024 | 51.6% |
Aurora Innovation (AUR) | 12/1/2023 - 1/3/2024 | 51.38% |
Arrowhead Pharmaceuticals (ARWR) | 12/1/2023 - 1/3/2024 | 48.35% |
Applied Digital (APLD) | 12/1/2023 - 1/3/2024 | 47.1% |
Travere Therapeutics (TVTX) | 12/1/2023 - 1/3/2024 | 46.3% |
Verona Pharma PLC ADR (VRNA) | 12/1/2023 - 1/3/2024 | 45.11% |
Sunrun (RUN) | 12/1/2023 - 1/3/2024 | 44.74% |
Recursion Pharmaceuticals (RXRX) | 12/1/2023 - 1/3/2024 | 43.34% |
Apogee Therapeutics, Inc Common Stock (APGE) | 12/1/2023 - 1/3/2024 | 43.19% |
Dave (DAVE) | 12/1/2023 - 1/3/2024 | 42.37% |
Cipher Mining (CIFR) | 12/1/2023 - 1/3/2024 | 40.36% |
Viking Therapeutics (VKTX) | 12/1/2023 - 1/3/2024 | 40.32% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
